ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: BMS Oncology Names New VP, Marketing; Hortobagyi Wins Freyer Medal; Prerez Honored

October 24, 1997

NCI Contract Process Requires Eight Months, Probably Will Get Longer As Program Grows

February 8, 1974

IVAX And It’s Portfolio

December 22, 1994

Clarification: Full Text Of ACS Guideline On Prostate Screening

January 30, 1998

In Brief: Cancer Act renewal, Appropriations Bill Caught In Squeeze Between Conventions

August 1, 1980

No Benefit For Radiation For Early Stage Disease Spread To Only One Node

March 26, 2010